April 18, 2024

An artist's interpretation of a futuristic medical laboratory highlighting the successful Phase III SELECT-GCA trial for Rinvoq, with scientists examining glowing test tubes and digital screens displaying giant cell arteritis data.

Promising Outcomes from Phase III SELECT-GCA Study of Rinvoq in Treating Giant Cell Arteritis Patients.

Frank Dolan April 18, 2024

Addex Therapeutics: 2023 Financial Results and Corporate Update

Arsenal April 18, 2024

TaiGen’s TG-1000 Influenza Antiviral Completes Successful Phase III Study

Arsenal April 18, 2024

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Breakthroughs at CROI 2023: Merck and ViiV Healthcare's Innovative Advances in HIV Treatment

Breakthroughs at CROI 2023: Merck and ViiV Healthcare’s Innovative Advances in HIV Treatment

Merck Triumphs in Court: Gardasil HPV Vaccine Risk Claims Dismissed by Judge

Merck Triumphs in Court: Gardasil HPV Vaccine Risk Claims Dismissed by Judge

Biotechs Trading Below Enterprise Value: Zombies, Comebacks, and Caution Ahead

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA